Stocktoria
Cyclerion Therapeutics, Inc. CYCN
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2019-03-18
Cyclerion Therapeutics, Inc. financials (annual)
Bars are annual figures from 2018 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.1M | $2.0M | $0 | $297,000 | $3.9M | $2.3M | $4.5M | — |
| R&D expense | $959,000 | $286,000 | $1.5M | $6.0M | $37.6M | $56.4M | $95.1M | $87.7M |
| Operating income | -$5.0M | -$3.6M | -$13.0M | -$18.5M | -$55.2M | -$81.3M | -$125.0M | -$115.3M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$3.5M | -$3.1M | -$5.3M | -$44.1M | -$51.6M | -$77.8M | -$123.0M | -$115.3M |
| EPS (diluted) | $-1.11 | $-1.21 | $-2.25 | $-20.28 | $-1.32 | — | — | — |
| Operating cash flow | -$3.3M | -$4.3M | -$21.2M | -$40.6M | -$36.5M | -$72.5M | -$102.2M | -$97.5M |
| Free cash flow | — | — | — | -$40.6M | -$36.5M | -$74.0M | -$109.1M | -$100.9M |
| Cash & equivalents | $3.2M | $3.2M | $7.6M | $13.4M | $54.0M | $54.4M | $94.9M | — |
| Total assets | $10.0M | $9.6M | $13.4M | $18.1M | $59.3M | $115.4M | $186.5M | $7.4M |
| Shareholders' equity | $9.1M | $8.8M | $11.3M | $10.5M | $48.2M | $59.5M | $97.7M | -$10.4M |
Growth · year-over-year · Revenue CAGR -12.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | +3.7% | — | -100.0% | -92.5% | +71.7% | -49.1% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.